Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

Author:

Dummer R.1ORCID,Guminksi A.234,Gutzmer R.5,Lear J.T.6,Lewis K.D.7,Chang A.L.S.8ORCID,Combemale P.910,Dirix L.11,Kaatz M.12,Kudchadkar R.13,Loquai C.14,Plummer R.15,Schulze H.‐J.16,Stratigos A.J.17,Trefzer U.18,Squittieri N.19,Migden M.R.20

Affiliation:

1. Department of Dermatology University of Zürich Skin Cancer Center University Hospital Zürich Switzerland

2. Department of Medical Oncology Royal North Shore Hospital Sydney Australia

3. Melanoma Institute Australia The University of Sydney Sydney Australia

4. Mater Hospital Sydney Australia

5. Skin Cancer Center Hannover Department of Dermatology Hannover Medical School Hannover Germany

6. Manchester Academic Health Science Centre Manchester University and Salford Royal NHS Trust Manchester U.K.

7. University of Colorado Cancer Center, Anschutz Aurora CO U.S.A.

8. Department of Dermatology Stanford University School of Medicine Redwood City CA U.S.A.

9. Department of Dermatology Hôpitaux Universitaires de Lyon Université de Lyon Lyon France

10. Centre de Référence des Neurofibromatoses Créteil France

11. Saint‐Augustinus Hospital Antwerp Belgium

12. Department of Dermatology SRH Waldklinikum Gera Germany

13. Emory University Atlanta GA U.S.A.

14. Department of Dermatology University Medical Center Mainz Mainz Germany

15. Northern Centre for Cancer Care The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne U.K.

16. Department of Dermatology Fachklinik Hornheide Münster Germany

17. First Department of Dermatology‐Venereology National and Kapodistrian University of Athens School of Medicine Andreas Sygros Hospital for Skin and Venereal Diseases Athens Greece

18. Department of Dermatology University Hospital Charite Berlin Germany

19. Sun Pharmaceutical Industries, Inc. Princeton NJ U.S.A.

20. Departments of Dermatology and Head and Neck Surgery The University of Texas‐MD Anderson Cancer Center Houston TX U.S.A.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Dermatology

Cited by 120 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3